Seeking Alpha

XPH
SPDR S&P Pharmaceuticals ETF

5/27/2012, 3:28 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
XPH Market Currents more »
  • April 30 Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees.
    Comment!
    [Healthcare, Quick Ideas]
ETF Stats
  • Expense Ratio: 0.36%
  • Average Bid Ask Ratio: 0.11%
  • Tracking Error: 0.12%
  • Concentration Risk: 8.95%
  • Capital Gains Dist. %: 0.16%
  • Number of Securities: 28
  • Dividend Amount: $0.117483
  • Dividend Date: 12/16/2011
For overall rating and ranking versus other ETFs get a free trial to XTF Premium
XPH in Focus more »
XPH News more »
XPH Press Releases and Filings more »
Currently, there are no press releases or filings on XPH.
XPH Instablog posts more »
Write a post on XPH
XPH StockTalks
XPH vs. ETF Alternatives
XPH Description
The SPDR® S&P® Pharmaceuticals ETF seeks to replicate as closely as possible, before expenses, the total return performance of the S&P Pharmaceuticals Select Industry® Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
Sector: Healthcare
Country: United States